Bright Minds Biosciences Inc. DRUG
CNSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 191.86% | 150.03% | 93.36% | 73.53% | 35.44% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 200.43% | -- | -- | -- | -- |
| Total Operating Expenses | 362.88% | 492.82% | 623.71% | 408.49% | 143.90% |
| Operating Income | -362.88% | -492.82% | -623.71% | -408.49% | -143.90% |
| Income Before Tax | -178.35% | -718.64% | -1,703.20% | -325.40% | -142.00% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -178.35% | -718.64% | -1,703.20% | -325.40% | -142.00% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -178.35% | -718.64% | -1,703.20% | -325.40% | -142.00% |
| EBIT | -362.88% | -492.82% | -623.71% | -408.49% | -143.90% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -119.48% | -549.61% | -982.94% | -143.02% | -39.00% |
| Normalized Basic EPS | -119.51% | -549.83% | -983.35% | -142.97% | -39.00% |
| EPS Diluted | -119.70% | -547.71% | -972.42% | -142.18% | -38.41% |
| Normalized Diluted EPS | -119.40% | -549.00% | -980.45% | -143.07% | -39.07% |
| Average Basic Shares Outstanding | 38.98% | 43.02% | 48.80% | 59.59% | 49.69% |
| Average Diluted Shares Outstanding | 36.36% | 40.01% | 45.27% | 62.35% | 52.57% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |